Clinical Trial

A Study of SHR-2524 Plus Bevacizumab in the First-line Treatment of Advanced Hepatocellular Carcinoma

Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
This study was a multicenter, open-label phase I clinical trial. This trial will include 36 patients with advanced unresectable hepatocellular carcinoma. Blood samples were obtained during the course of treatment to measure the relative parameter. All Investigational Medicinal Products (IMP) were discontinued after the total cycle.
Protocol Amendment History 1 change
critical Recruitment opened 2026-04-30
Trial Details
NCT Number NCT07478302
Lead Sponsor Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Conditions Advanced Unresectable Hepatocellular Carcinoma
Enrollment 36 participants
Start Date 2026-04-14
Primary Completion 2027-10 (estimated)
Study Completion 2027-12 (estimated)
Updated on ClinicalTrials.gov 2026-05-01